An integrative analysis of genomic, transcriptomic and proteomic data on KRAS mutated lung adenocarcinoma patients shown that the most frequent co-occurring genomic alterations, together with KRAS mutation, are the loss of STK11/LKB1 or TP53 functions. The gene discussed is STK11; the disease is lung adenocarcinoma.